# A Study of Imatinib With Reinduction Chemotherapy Using Mitoxantrone, Etoposide and Cytarabine in Patients With Relapsed/Refractory C-kit Positive (AML) Acute Myeloid Leukemia

> **NCT01126814** · PHASE1,PHASE2 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 35 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** Imatinib (Gleevec)

## Key facts

- **NCT ID:** NCT01126814
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** 2009-09
- **Final completion:** 2010-04
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2015-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01126814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01126814, "A Study of Imatinib With Reinduction Chemotherapy Using Mitoxantrone, Etoposide and Cytarabine in Patients With Relapsed/Refractory C-kit Positive (AML) Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01126814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*